{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T16:54:11Z","timestamp":1792601651223,"version":"4.5.0"},"reference-count":22,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T00:00:00Z","timestamp":1782259200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>\n                      Accurate staging is paramount for the effective management of medullary thyroid carcinoma (MTC). Imaging cancer-associated fibroblasts utilizing Gallium-68-labeled fibroblast activation protein inhibitors (FAPI) presents a novel approach for molecular imaging across various cancers, including MTC. This study aimed to compare the diagnostic accuracy of FAP-targeted imaging (\n                      <jats:sup>68<\/jats:sup>\n                      Ga-RTX-1363S, abbreviated as\n                      <jats:sup>68<\/jats:sup>\n                      Ga-FAPI) with the established imaging standard,\n                      <jats:sup>18<\/jats:sup>\n                      F-DOPA, for the detection of metastases in patients with MTC.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      This retrospective study compared\n                      <jats:sup>18<\/jats:sup>\n                      F-DOPA- and\n                      <jats:sup>68<\/jats:sup>\n                      Ga-FAPI PET\/CT imaging using per-patient and per-lesion analyses in patients with recurrent MTC. Imaging findings were correlated with morphological imaging (CT\/MRI\/sonography) or histopathology as gold standard. Quantitative assessment included a comparison of standardized uptake values (SUVs) and tumor-to-background ratios (TBRs).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Nine patients (mean age 55 years, range 34\u201380 years) with 62 lesions were included. Compared to\n                      <jats:sup>18<\/jats:sup>\n                      F-DOPA,\n                      <jats:sup>68<\/jats:sup>\n                      Ga-FAPI showed significantly higher lesion detection rates for lymph node metastases (true-positive [TP] rate: 100% [8\/8] vs. 50% [4\/8]; TBR: 10.9 vs. 6.9), lung metastases (TP rate: 85.7% [12\/14] vs. 42.9% [6\/14]; TBR: 6.1 vs. 3.6), and liver metastases (TP rate: 100% [22\/22] vs. 23% [5\/22]; TBR: 24.1 vs. 2.7).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      In direct comparison,\n                      <jats:sup>68<\/jats:sup>\n                      Ga-FAPI detected a higher number of metastases with higher TBR values.\n                      <jats:sup>68<\/jats:sup>\n                      Ga-FAPI PET\/CT holds promise for improving staging in MTC. However, these findings necessitate confirmation in a larger, prospective study.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fendo.2026.1824054","type":"journal-article","created":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T08:51:46Z","timestamp":1782291106000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Comparison of 68Ga-FAPI and 18F-DOPA PET\/CT in patients with medullary thyroid cancer"],"prefix":"10.3389","volume":"17","author":[{"given":"Daniel A.","family":"Hescheler","sequence":"first","affiliation":[{"name":"University Hospital Magdeburg, Division of Nuclear Medicine, Department of Radiology and Nuclear Medicine","place":["Magdeburg, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dogan","family":"Atiyat","sequence":"additional","affiliation":[{"name":"Martin Luther University of Halle Wittenberg Faculty of Medicine, Department of Nuclear Medicine","place":["Halle (Saale), Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerstin","family":"Lorenz","sequence":"additional","affiliation":[{"name":"Martin Luther University Halle-Wittenberg, Halle (Saale), Department of General, Visceral and Vascular Surgery","place":["Halle (Saale), Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Heinzel","sequence":"additional","affiliation":[{"name":"Martin Luther University Halle-Wittenberg, Halle (Saale), Department of Nuclear Medicine","place":["Halle (Saale), Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"Reschke","sequence":"additional","affiliation":[{"name":"Martin Luther University Halle-Wittenberg, Halle (Saale), Department of Nuclear Medicine","place":["Halle (Saale), Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frankis G.","family":"Almaguel","sequence":"additional","affiliation":[{"name":"University Hospital Frankfurt, Department of Radiology","place":["Frankfurt, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuela","family":"Petersen","sequence":"additional","affiliation":[{"name":"Loma Linda University Medical Center, Department of Radiology","place":["Loma Linda, CA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth","family":"Eppard","sequence":"additional","affiliation":[{"name":"University Hospital Magdeburg, Division of Nuclear Medicine, Department of Radiology and Nuclear Medicine","place":["Magdeburg, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna","family":"Wybranska","sequence":"additional","affiliation":[{"name":"University Hospital Magdeburg, Division of Nuclear Medicine, Department of Radiology and Nuclear Medicine","place":["Magdeburg, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Wuestemann","sequence":"additional","affiliation":[{"name":"University Hospital Magdeburg, Division of Nuclear Medicine, Department of Radiology and Nuclear Medicine","place":["Magdeburg, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael C.","family":"Kreissl","sequence":"additional","affiliation":[{"name":"University Hospital Magdeburg, Division of Nuclear Medicine, Department of Radiology and Nuclear Medicine","place":["Magdeburg, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,6,24]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1089\/thy.2014.0335","article-title":"Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma","volume":"25","author":"Wells","year":"2015","journal-title":"Thyroid"},{"key":"B2","article-title":"Medullary thyroid cancer","volume-title":"Statpearls","author":"Ramos Santillan","year":"2024"},{"key":"B3","unstructured":"Medullary Thyroid Cancer"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/s0950-351x(95)80638-5","article-title":"RET proto-oncogene mutations in multiple endocrine neoplasia type 2 and medullary thyroid carcinoma","volume":"9","author":"Cote","year":"1995","journal-title":"Baillieres Clin Endocrinol Metab"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.864253","article-title":"Sporadic medullary thyroid carcinoma: Towards a precision medicine","volume":"13","author":"Matrone","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1053\/j.semnuclmed.2023.01.003","article-title":"Update on management of medullary thyroid carcinoma: Focus on nuclear medicine","volume":"53","author":"Treglia","year":"2023","journal-title":"Semin Nucl Med"},{"key":"B7","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1007\/s002590000404","article-title":"18F-DOPA positron emission tomography for tumour detection in patients with medullary thyroid carcinoma and elevated calcitonin levels","volume":"28","author":"Hoegerle","year":"2001","journal-title":"Eur J Nucl Med"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/324686","article-title":"PET imaging in recurrent medullary thyroid carcinoma","volume":"2012","author":"Treglia","year":"2012","journal-title":"Int J Mol Imaging"},{"key":"B9","first-page":"67","article-title":"Role of PET in medullary thyroid carcinoma","volume":"33","author":"Rufini","year":"2008","journal-title":"Minerva Endocrinol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1007\/s00259-019-04458-6","article-title":"EANM practice guideline for PET\/CT imaging in medullary thyroid carcinoma","volume":"47","author":"Giovanella","year":"2020","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.118.215913","article-title":"68Ga-FAPI PET\/CT: Biodistribution and preliminary dosimetry estimate of 2 DOTA-containing FAP-targeting agents in patients with various cancers","volume":"60","author":"Giesel","year":"2019","journal-title":"J Nucl Med"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1053\/j.semnuclmed.2023.11.003","article-title":"How to perform FAPI PET? An expedited systematic review providing a recommendation for FAPI PET imaging with different FAPI tracers","volume":"54","author":"Bentestuen","year":"2024","journal-title":"Semin Nucl Med"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.119.227967","article-title":"68Ga-FAPI PET\/CT: Tracer uptake in 28 different kinds of cancer","volume":"60","author":"Kratochwil","year":"2019","journal-title":"J Nucl Med"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-023-06348-4","article-title":"68Ga]Ga-DOTA-FAPI-04 PET\/CT depicts metastases from medullary thyroid cancer that [68Ga]Ga-DOTATOC PET\/CT missed","volume":"50","author":"Al-Ibraheem","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"B15","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1089\/thy.2008.0403","article-title":"Medullary thyroid cancer: Management guidelines of the American Thyroid Association","volume":"19","author":"Kloos","year":"2009","journal-title":"Thyroid"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-018-4045-9","article-title":"18F]DOPA PET\/ceCT in diagnosis and staging of primary medullary thyroid carcinoma prior to surgery","volume":"45","author":"Rasul","year":"2018","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-014-2961-x","article-title":"FDG PET\/CT: EANM procedure guidelines for tumour imaging: version 2.0","volume":"42","author":"Boellaard","year":"2015","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.2967\/jnmt.119.236109","article-title":"Assessing PET parameters in oncologic 18F-FDG studies","volume":"48","author":"Sarikaya","year":"2020","journal-title":"J Nucl Med Technol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.111.094771","article-title":"Complementary roles of 18F-DOPA PET\/CT and 18F-FDG PET\/CT in medullary thyroid cancer","volume":"52","author":"Kauhanen","year":"2011","journal-title":"J Nucl Med"},{"key":"B20","article-title":"Role of (18) F-FDOPA PET\/CT imaging in endocrinology","volume-title":"Clin Endocrinol (Oxf)","author":"Santhanam","year":"2014"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1038\/nrc.2016.73","article-title":"The biology and function of fibroblasts in cancer","volume":"16","author":"Kalluri","year":"2016","journal-title":"Nat Rev Cancer"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-011-2031-6","article-title":"Comparison of 18F-DOPA, 18F-FDG and 68Ga-somatostatin analogue PET\/CT in patients with recurrent medullary thyroid carcinoma","volume":"39","author":"Treglia","year":"2012","journal-title":"Eur J Nucl Med Mol Imaging"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1824054\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T08:51:52Z","timestamp":1782291112000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1824054\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,24]]},"references-count":22,"alternative-id":["10.3389\/fendo.2026.1824054"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2026.1824054","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,24]]},"article-number":"1824054"}}